{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:52:44Z","timestamp":1794059564610,"version":"4.8.0"},"reference-count":45,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2023,9,27]]},"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Hereditary transthyretin amyloidosis is a life-threatening autosomal dominant systemic disease due to pathogenic<jats:italic>TTR<\/jats:italic>variants (ATTRv), mostly affecting the peripheral nerves and heart. The disease is characterised by a combination of symptoms, organ involvement and histological amyloid deposition. The available disease-modifying ATTRv treatments (DMTs) are more effective if initiated early. Pathological nerve conduction studies (NCS) results are the cornerstone of large-fibre polyneuropathy diagnosis, but this anomaly occurs late in the disease. We investigated the utility of a multimodal neurological and cardiac evaluation for detecting early disease onset in ATTRv carriers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively analysed a cohort of ATTRv carriers with normal NCS results regardless of symptoms. Multimodal denervation and infiltration evaluations included a clinical questionnaire (Lauria and New York Heart Association (NYHA)) and examination, intra-epidermal nerve fibre density assessment, autonomic assessment based on heart rate variability, Sudoscan, meta-iodo-benzyl-guanidine scintigraphy, cardiac biomarkers, echocardiography, MRI and searches for amyloidosis on skin biopsy and bone scintigraphy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 130 ATTRv carriers (40.8% men, age: 43.6\u00b113.5 years), with 18 amyloidogenic<jats:italic>TTR<\/jats:italic>gene mutations, the majority of which was the late-onset Val30Met variant (42.3%). Amyloidosis was detected in 16.9% of mutation carriers, including 9 (6.9%) with overt disease (Lauria&gt;2\u2009or NYHA&gt;1) and 13 asymptomatic carriers (10%) with organ involvement (small-fibre neuropathy or cardiomyopathy). Most of these patients received DMT. Abnormal test results of unknown significance were obtained for 105 carriers (80.8%). Investigations were normal in only three carriers (2.3%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Multimodal neurological and cardiac investigation of TTRv carriers is crucial for the early detection of ATTRv amyloidosis and initiation of DMT.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2023-332180","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T17:23:45Z","timestamp":1698168225000},"page":"489-499","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers"],"prefix":"10.1136","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8323-8767","authenticated-orcid":false,"given":"Diane","family":"Beauvais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Labeyrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Cauquil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Francou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludivine","family":"Eliahou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeline","family":"Not","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andoni","family":"Echaniz-Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clovis","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel S","family":"Slama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouar","family":"Benmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Rouzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Algalarrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillemette","family":"Beaudonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"2025032210451038000_95.6.489.1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22619"},{"key":"2025032210451038000_95.6.489.2","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320600606"},{"key":"2025032210451038000_95.6.489.3","doi-asserted-by":"publisher","DOI":"10.1159\/000053996"},{"key":"2025032210451038000_95.6.489.4","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000132966.36437.12"},{"key":"2025032210451038000_95.6.489.5","doi-asserted-by":"crossref","DOI":"10.1136\/jmg.40.11.e120","article-title":"Genetic study of transthyretin amyloid neuropathies: carrier risks among French and portuguese families","volume":"40","author":"Plant\u00e9-Bordeneuve","year":"2003","journal-title":"J Med Genet"},{"key":"2025032210451038000_95.6.489.6","doi-asserted-by":"publisher","DOI":"10.1080\/13506120802193720"},{"key":"2025032210451038000_95.6.489.7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182661eb1"},{"key":"2025032210451038000_95.6.489.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"2025032210451038000_95.6.489.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"2025032210451038000_95.6.489.10","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2022.2091985"},{"key":"2025032210451038000_95.6.489.11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126526","article-title":"Predictive model of response to tafamidis in hereditary ATTR polyneuropathy","volume":"4","author":"Monteiro","year":"2019","journal-title":"JCI Insight"},{"key":"2025032210451038000_95.6.489.12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13506129.2022.2118043","article-title":"Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial","volume":"30","author":"Quan","year":"2023","journal-title":"Amyloid"},{"key":"2025032210451038000_95.6.489.13","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/brain\/123.7.1495","article-title":"The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation","volume":"123 (Pt 7)","author":"Adams","year":"2000","journal-title":"Brain"},{"key":"2025032210451038000_95.6.489.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2016.07.008"},{"key":"2025032210451038000_95.6.489.15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S1474-4422(20)30368-9","article-title":"Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study","volume":"20","author":"Adams","year":"2021","journal-title":"Lancet Neurol"},{"key":"2025032210451038000_95.6.489.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"2025032210451038000_95.6.489.17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/13506129.2019.1627312","article-title":"Assessment of patients with hereditary transthyretin amyloidosis \u2013 understanding the impact of management and disease progression","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"2025032210451038000_95.6.489.18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.neurol.2016.08.007","article-title":"Familial amyloid polyneuropathy: when does it stop to be asymptomatic and need a treatment?","volume":"172","author":"Adams","year":"2016","journal-title":"Rev Neurol (Paris)"},{"key":"2025032210451038000_95.6.489.19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ana.25433","article-title":"Skin nerve pathology: biomarkers of premanifest and manifest amyloid neuropathy","volume":"85","author":"Chao","year":"2019","journal-title":"Ann Neurol"},{"key":"2025032210451038000_95.6.489.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2016.02.013"},{"key":"2025032210451038000_95.6.489.21","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0b013e32835804c5"},{"key":"2025032210451038000_95.6.489.22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181bacf05"},{"key":"2025032210451038000_95.6.489.23","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15268"},{"key":"2025032210451038000_95.6.489.24","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12842"},{"key":"2025032210451038000_95.6.489.25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/dia.2015.0396","article-title":"Normative values for electrochemical skin conductances and impact of ethnicity on quantitative assessment of sudomotor function","volume":"18","author":"Vinik","year":"2016","journal-title":"Diabetes Technol Ther"},{"key":"2025032210451038000_95.6.489.26","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2017.00258","article-title":"An overview of heart rate variability metrics and norms","volume":"5","author":"Shaffer","year":"2017","journal-title":"Front Public Health"},{"key":"2025032210451038000_95.6.489.27","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S0140-6736(67)93028-0","article-title":"Control of heart-rate in healthy young men","volume":"290","author":"Sutton","year":"1967","journal-title":"Lancet"},{"key":"2025032210451038000_95.6.489.28","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s00259-018-3963-x","article-title":"Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers","volume":"45","author":"Piekarski","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2025032210451038000_95.6.489.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.05.073"},{"key":"2025032210451038000_95.6.489.30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"2025032210451038000_95.6.489.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2009.09.023"},{"key":"2025032210451038000_95.6.489.32","doi-asserted-by":"publisher","DOI":"10.1093\/ejechocard\/jep194"},{"key":"2025032210451038000_95.6.489.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.05.053"},{"key":"2025032210451038000_95.6.489.34","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1212\/WNL.0000000000004016","article-title":"Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy","volume":"88","author":"Masuda","year":"2017","journal-title":"Neurology"},{"key":"2025032210451038000_95.6.489.35","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/acn3.51636","article-title":"Cutaneous amyloid is a biomarker in early attrv neuropathy and progresses across disease stages","volume":"9","author":"Freeman","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"2025032210451038000_95.6.489.36","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12585"},{"key":"2025032210451038000_95.6.489.37","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2020.1744553","article-title":"The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30m mutation depends on the phenotypic expression of the disease","volume":"27","author":"Azevedo Coutinho","year":"2020","journal-title":"Amyloid"},{"key":"2025032210451038000_95.6.489.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63050-7"},{"key":"2025032210451038000_95.6.489.39","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.clinph.2018.05.005","article-title":"The value of electrochemical skin conductance measurement using sudoscan\u00ae in the assessment of patients with familial amyloid polyneuropathy","volume":"129","author":"Lefaucheur","year":"2018","journal-title":"Clin Neurophysiol"},{"key":"2025032210451038000_95.6.489.40","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1097\/WCO.0000000000000290","article-title":"Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis","volume":"29 Suppl 1","author":"Obici","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"2025032210451038000_95.6.489.41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/WNL.0000000000004178","article-title":"Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools","volume":"89","author":"Kollmer","year":"2017","journal-title":"Neurology"},{"key":"2025032210451038000_95.6.489.42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00415-020-10127-8","article-title":"Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers","volume":"268","author":"Salvalaggio","year":"2021","journal-title":"J Neurol"},{"key":"2025032210451038000_95.6.489.43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/13506129.2022.2155132","article-title":"Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients","volume":"30","author":"Concei\u00e7\u00e3o","year":"2023","journal-title":"Amyloid"},{"key":"2025032210451038000_95.6.489.44","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1212\/WNL.0000000000011090","article-title":"Neurofilament light chain as a biomarker of hereditary transthyretin-mediated amyloidosis","volume":"96","author":"Ticau","year":"2021","journal-title":"Neurology"},{"key":"2025032210451038000_95.6.489.45","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/13506129.2022.2070470","article-title":"A natural history analysis of asymptomatic TTR gene carriers as they develop symptomatic transthyretin amyloidosis in the transthyretin amyloidosis outcomes survey (THAOS)","volume":"29","author":"Coelho","year":"2022","journal-title":"Amyloid"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2023-332180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T17:50:56Z","timestamp":1742665856000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2023-332180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,5,14]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1136\/jnnp-2023-332180"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2023-332180","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]}}}